{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:11:14Z","timestamp":1790356274052,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Contingency management (CM) is an effective intervention that provides financial incentives as positive reinforcement for reducing opioid or stimulant use. However, it has not been tested in populations of women who inject drugs (WWID) engaging in polysubstance use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We aimed to compare the feasibility of two CM protocols designed to encourage illicit stimulant and opioid abstinence among WWID participating in an ongoing HIV prevention trial. Participants completed a 3-month CM period during which they submitted thrice weekly urine toxicology screenings (UTOX). In the \u2018abstinence from stimulants and opioids\u2019 protocol, participants received a $5 USD incentive when metabolites of stimulants and opioids were not detected in urine. In the \u2018partial-abstinence protocol\u2019, they received a $5 USD incentive when metabolites of stimulants or opioids were not detected, thus doubling the potential incentive obtained each visit. Women also received scaling bonuses after three consecutive negative UTOX ($5-$15 USD). We used descriptive statistics to summarize the total number of (1) UTOXs completed and (2) bonuses distributed. Rates of engagement per person per month were calculated (i.e., total number of completed UTOX\/3 months*24 participants). Rates of engagement were compared by CM protocol period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants were primarily White women (67%) with an average age of 47 years. Self-reported polysubstance use was common (96%) with women reporting injecting an average of 5 times daily (Interquartile Range: 2\u20137). Participants (<jats:italic>N<\/jats:italic>\u2009=\u200924) collectively submitted 177 UTOX during their 3-month CM periods. Rates of non-reactive UTOX results were slightly higher in the partial-abstinence protocol compared to the abstinence from stimulants and opioids protocol (2.9 per month versus 1.0 per month). More bonuses were earned in the partial-abstinence protocol (0.50 bonuses per participant per month) compared to the abstinence from stimulants and opioids protocol (none). There were no study related adverse events in either protocol group during the CM period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Findings demonstrate the feasibility of a CM protocol that provided financial incentives for partial abstinence, periods with documented stimulant or opioid abstinence, as well as abstinence to both, without the occurrence of iatrogenic effects. Future research focusing on CM protocols with more flexible incentive structures remains critical.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>NCT05192434.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00590-x","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T06:36:09Z","timestamp":1754634969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Implementation of contingency management with women engaging in polysubstance use"],"prefix":"10.1186","volume":"20","author":[{"given":"Kathleen M.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam W.","family":"Carrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene\u00e9 H.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Rivet","family":"Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison K.","family":"Groves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scarlett L.","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Krakower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Mazzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis M.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"590_CR1","doi-asserted-by":"crossref","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u2013350.","DOI":"10.1097\/YCO.0000000000000717"},{"key":"590_CR2","doi-asserted-by":"publisher","first-page":"102642","DOI":"10.1016\/j.drugpo.2019.102642","volume":"76","author":"KE Schneider","year":"2020","unstructured":"Schneider KE, O\u2019Rourke A, White RH, Park JN, Musci RJ, Kilkenny ME, et al. Polysubstance use in rural West virginia: associations between latent classes of drug use, overdose, and take-home Naloxone. Int J Drug Policy. 2020;76:102642.","journal-title":"Int J Drug Policy"},{"key":"590_CR3","doi-asserted-by":"crossref","unstructured":"Shover CL, Friedman JR, Romero R, Jimenez S, Beltran J, Garcia C et al. Leveraging pooled medical examiner records to surveil complex and emerging patterns of polysubstance use in the united States. Int J Drug Policy. 2025;141:104397.","DOI":"10.1016\/j.drugpo.2024.104397"},{"issue":"3","key":"590_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/alcalc\/agac006","volume":"57","author":"SR Goodwin","year":"2022","unstructured":"Goodwin SR, Moskal D, Marks RM, Clark AE, Squeglia LM, Roche DJO. A scoping review of gender, sex and sexuality differences in polysubstance use in adolescents and adults. Alcohol Alcohol. 2022;57(3):292\u2013321.","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"590_CR5","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"590_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","volume":"384","author":"H Trivedi Madhukar","year":"2021","unstructured":"Trivedi Madhukar H, Walker R, Ling W, dela Cruz A, Sharma G, Carmody T, et al. Bupropion and Naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140\u201353.","journal-title":"N Engl J Med"},{"issue":"3","key":"590_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","volume":"77","author":"PO Coffin","year":"2020","unstructured":"Coffin PO, Santos GM, Hern J, Vittinghoff E, Walker JE, Matheson T, et al. Effects of Mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: A Placebo-Controlled randomized clinical trial. JAMA Psychiatry. 2020;77(3):246\u201355.","journal-title":"JAMA Psychiatry"},{"key":"590_CR8","doi-asserted-by":"publisher","first-page":"108060","DOI":"10.1016\/j.drugalcdep.2020.108060","volume":"212","author":"PV AshaRani","year":"2020","unstructured":"AshaRani PV, Hombali A, Seow E, Ong WJ, Tan JH, Subramaniam M. Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020;212:108060.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"590_CR9","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/j.1360-0443.2006.01581.x","volume":"101","author":"M Prendergast","year":"2006","unstructured":"Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101(11):1546\u201360.","journal-title":"Addiction"},{"issue":"1","key":"590_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1037\/ccp0000552","volume":"89","author":"MK Ginley","year":"2021","unstructured":"Ginley MK, Pfund RA, Rash CJ, Zajac K. Long-term efficacy of contingency management treatment based on objective indicators of abstinence from illicit substance use up to 1 year following treatment: A meta-analysis. J Consult Clin Psychol. 2021;89(1):58\u201371.","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"590_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1192\/pb.bp.110.031831","volume":"35","author":"NM Petry","year":"2011","unstructured":"Petry NM. Contingency management: what it is and why psychiatrists should want to use it. Psychiatrist. 2011;35(5):161\u20133.","journal-title":"Psychiatrist"},{"issue":"9","key":"590_CR12","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1176\/ajp.148.9.1218","volume":"148","author":"ST Higgins","year":"1991","unstructured":"Higgins ST, Delaney DD, Budney AJ, Bickel WK, Hughes JR, Foerg F, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry. 1991;148(9):1218\u201324.","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"590_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0376-8716(99)00071-X","volume":"58","author":"NM Petry","year":"2000","unstructured":"Petry NM. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug Alcohol Depend. 2000;58(1\u20132):9\u201325.","journal-title":"Drug Alcohol Depend"},{"key":"590_CR14","doi-asserted-by":"publisher","first-page":"209012","DOI":"10.1016\/j.josat.2023.209012","volume":"151","author":"H Breland","year":"2023","unstructured":"Breland H, Larkins S, Antonini V, Freese T, McGovern M, Dunn J, et al. Stimulant use among patients in opioid treatment settings: provider perspectives. J Subst Use Addict Treat. 2023;151:209012.","journal-title":"J Subst Use Addict Treat"},{"issue":"2","key":"590_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/29767342231221060","volume":"45","author":"RD Shearer","year":"2024","unstructured":"Shearer RD, Hernandez E, Beebe TJ, Virnig BA, Bart G, Winkelman TNA, et al. Providers\u2019 experiences and perspectives in treating patients with Co-Occurring opioid and stimulant use disorders in the hospital. Subst Use Addict J. 2024;45(2):250\u20139.","journal-title":"Subst Use Addict J"},{"issue":"9","key":"590_CR16","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/add.16497","volume":"119","author":"GK Khazanov","year":"2024","unstructured":"Khazanov GK, McKay JR, Rawson R. Should contingency management protocols and dissemination practices be modified to accommodate rising stimulant use and harm reduction frameworks? Addiction. 2024;119(9):1505\u201314.","journal-title":"Addiction"},{"key":"590_CR17","unstructured":"Roth AM. Trauma Intervention to Optimize PrEP Among Women Who Inject Drugs (TIARAS). Clinical Trials Identifier: NCT05192434. ClinicalTrials.gov2023 [updated 23 April 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05192434"},{"issue":"3","key":"590_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s10865-016-9713-2","volume":"39","author":"AW Carrico","year":"2016","unstructured":"Carrico AW, Nil E, Sophal C, Stein E, Sokunny M, Yuthea N, et al. Behavioral interventions for Cambodian female entertainment and sex workers who use amphetamine-type stimulants. J Behav Med. 2016;39(3):502\u201310.","journal-title":"J Behav Med"},{"key":"590_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.drugalcdep.2018.11.029","volume":"196","author":"K Page","year":"2019","unstructured":"Page K, Carrico AW, Stein E, Evans J, Sokunny M, Maly P, et al. Cluster randomized stepped-wedge trial of a multi-level HIV prevention intervention to decrease amphetamine-type stimulants and sexual risk in Cambodian female entertainment and sex workers. Drug Alcohol Depend. 2019;196:21\u201330.","journal-title":"Drug Alcohol Depend"},{"key":"590_CR20","doi-asserted-by":"publisher","first-page":"108162","DOI":"10.1016\/j.drugalcdep.2020.108162","volume":"214","author":"RD Shearer","year":"2020","unstructured":"Shearer RD, Howell BA, Bart G, Winkelman TNA. Substance use patterns and health profiles among US adults who use opioids, methamphetamine, or both, 2015\u20132018. Drug Alcohol Depend. 2020;214:108162.","journal-title":"Drug Alcohol Depend"},{"key":"590_CR21","doi-asserted-by":"publisher","first-page":"107703","DOI":"10.1016\/j.ypmed.2023.107703","volume":"176","author":"TE Freese","year":"2023","unstructured":"Freese TE, Rutkowski BA, Peck JA, Urada D, Clark HW, Bland AN, et al. Recovery incentives program: california\u2019s contingency management benefit. Prev Med. 2023;176:107703.","journal-title":"Prev Med"},{"key":"590_CR22","doi-asserted-by":"publisher","first-page":"108307","DOI":"10.1016\/j.drugalcdep.2020.108307","volume":"216","author":"HD Brown","year":"2020","unstructured":"Brown HD, DeFulio A. Contingency management for the treatment of methamphetamine use disorder: A systematic review. Drug Alcohol Depend. 2020;216:108307.","journal-title":"Drug Alcohol Depend"},{"key":"590_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.addbeh.2018.03.018","volume":"84","author":"AF Waters","year":"2018","unstructured":"Waters AF, Businelle MS, Frank SG, H\u00e9bert ET, Kendzor DE. Understanding the link between contingency management and smoking cessation: the roles of sex and self-efficacy. Addict Behav. 2018;84:99\u2013105.","journal-title":"Addict Behav"},{"issue":"5","key":"590_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1037\/pha0000035","volume":"23","author":"CJ Rash","year":"2015","unstructured":"Rash CJ, Petry NM. Contingency management treatments are equally efficacious for both sexes in intensive outpatient settings. Exp Clin Psychopharmacol. 2015;23(5):369\u201376.","journal-title":"Exp Clin Psychopharmacol"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00590-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00590-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00590-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:11:23Z","timestamp":1757355083000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00590-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00590-x","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors KMW, AWC, DV, RHM, RA, AKG, SLB, SGS, SM, and AMR declare that they have no competing interests. DK has conducted research on HIV prevention funded by grants from Gilead and Merck to his institution and has received personal fees for developing medical education content for Medscape, Virology Education, and UpToDate, Inc., and travel support from PrEP4All.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All research was approved by Drexel University Institutional Review Board (IRB) and Philadelphia Department of Public Health IRB. All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"63"}}